Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
- Medical Reconstructive Tattoo Artistry by Alice Nicholls - 24th November 2020
- Asthma UK: switch from steroid to biologic treatments - 23rd November 2020
- Food health star rating can improve diets - 23rd November 2020